Printer Friendly

Molecular Assemblies Expands Patent Portfolio in Enzymatic DNA Synthesis.

M2 PHARMA-September 19, 2018-Molecular Assemblies Expands Patent Portfolio in Enzymatic DNA Synthesis

(C)2018 M2 COMMUNICATIONS

- US-based biotechnology company Molecular Assemblies, Inc. has recently been awarded three patents, bringing the total to eight issued patents protecting the company's proprietary enzymatic DNA synthesis technology in the United States and Europe, the company said.

The three issued patents are EP 3115462, US 10,041,110, and US 10,059,929.

Synthetic DNA is used in a range of applications, including life science research, biologic therapeutics, data storage, nanotechnology and industrial processes (including agriculture, plastics, fermentation, and even leather production).

However, its full potential has not been realized due to the cumbersome process of chemical DNA synthesis.

The three-decade-old method for synthesizing DNA is inherently limited to short DNA sequences, it requires extensive post-synthesis processing and uses hazardous chemicals.

In contrast, Molecular Assemblies enzymatic DNA synthesis delivers higher purity, can scale to longer DNA sequences, uses aqueous, non-toxic reagents, and does not require purification and processing.

Scientists at Molecular Assemblies have developed a novel, two-step enzymatic DNA synthesis method. It is performed in a water-based solution, eliminating many post-synthesis processing steps and reducing toxic chemical use.

In addition, the patents cover a modified enzyme that has increased capabilities relative to the wild type protein.

Molecular Assemblies' enzymatic approach is designed to reliably, affordably, and sustainably produce long, high quality DNA.

Molecular Assemblies is a private biotech company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products.

The company's patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably.

Molecular Assemblies said its technology will enable the reading and writing of DNA for industries including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. Molecular Assemblies is headquartered in San Diego.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 19, 2018
Words:328
Previous Article:Molecular Templates and Takeda to jointly develop potential new treatment for multiple myeloma.
Next Article:Agendia and Genecast Biotechnology Partner to Launch MammaPrint and BluePrint in China.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters